2026-04-14T03:53:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1711812025-12-04T19:02:32Zcom_2072_1057col_2072_478777col_2072_478917

urn:hdl:2445/171181 Ex vivo culture of lesional psoriasis skin for pharmacological testing Tiirikainen, Minna Lund Woetmann, Anders Norsgaard, Hanne Santamaria Babí, Luis F. Lovato, Paola Psoriasi Immunoregulació Psoriasis Immunoregulation Background: Psoriasis is a chronic, inflammatory skin disorder resulting from a complex interplay between immune and skin cells via release of soluble mediators. While a lot is known about the molecular mechanisms behind psoriasis pathogenesis, there is still a need for preclinical research models that accuratelyreplicate the disease. Objective: This study aimed to develop and characterize ex vivo culture of psoriasis skin as a model for pharmacological testing, where the immunological events of psoriasis can be followed. Methods: Full thickness punch biopsies of lesional psoriasis skin were cultured in submerged conditions up to 144 h followingin situ T cell stimulation with rhIL-23 and anti-CD3 and anti-CD28 antibodies. The Tcell mediated skin inflammation was assessed by gene and protein l analysis for a panel of inflammatory mediators. Tissue integrity and morphology were evaluated by histological analysis. Results: T cell stimulation resulted in functional and psoriasis specificin situ activation of T cells. The expression levels of most of the proinflammatory mediators related to both immune and skin cells were comparable to these in freshly isolated tissue at 48 and 96 h of culture. Tissue integrity and morphology were sustained up to 96 h. Treatment with a corticosteroid reduced the expression of several proinflammatory cytokines and chemokines, whereas anti-IL-17A antibody treatment reduced the expression of the IL-17A downstream markers IL-8 and DEFB4. Conclusion: By preserving keyimmunopathological mechanisms of psoriasis, ex vivo culture of psoriasis skin can be used for the investigation of inflammatory processes of psoriasis and for preclinical drug discovery research. 2020-10-13T14:23:03Z 2020-10-13T14:23:03Z 2019-12-27 2020-10-13T14:23:03Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1016/j.jdermsci.2019.12.010 Journal of Dermatological Science, 2019, vol. 97, num. 2, p. 109-116 https://doi.org/10.1016/j.jdermsci.2019.12.010 cc-by-nc-nd (c) Tiirikainen et al., 2019 http://creativecommons.org/licenses/by-nc-nd/3.0/es info:eu-repo/semantics/openAccess Elsevier Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)